IDiyas

For the Inventor, By the Inventor

Oak Park, CA, United States of America

Vu Van Ma

USPTO Granted Patents = 25 

 

 

Average Co-Inventor Count = 11.3

ph-index = 6

Forward Citations = 188(Granted Patents)


Location History:

  • Simi Valley, CA (US) (2008 - 2014)
  • Thousand Oaks, CA (US) (2021)
  • Oak Park, CA (US) (2014 - 2024)

Company Filing History:

goldMedal25 out of 1,970 
 
Amgen Inc.
 patents

Years Active: 2008-2025

Loading Chart...
Loading Chart...
Loading Chart...
25 patents (USPTO):
1. 12473289 - Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use (2025-11-18),
2. 12459932 - KIF18A inhibitors (2025-11-04),
3. 12440491 - KRAS G12C inhibitors and methods of using the same (2025-10-14),
4. 12083121 - Substituted piperazines as KRAS G12C inhibitors (2024-09-10),
5. 12054476 - KIF18A inhibitors (2024-08-06),
6. 11766436 - KRAS G12C inhibitors and methods of using the same (2023-09-26),
7. 11285156 - Substituted piperazines as KRAS G12C inhibitors (2022-03-29),
8. 11279712 - Macrocyclic compounds that inhibit MCL-1 protein (2022-03-22),
9. 11090304 - KRAS G12C inhibitors and methods of using the same (2021-08-17),
10. 11053226 - KRAS G12C inhibitors and methods of using the same (2021-07-06),
11. 10889581 - Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use (2021-01-12),
12. 9611261 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-04-04),
13. 9550762 - Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use (2017-01-24),
14. 9096527 - TRPM8 antagonists and their use in treatments (2015-08-04),
15. 9085576 - Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use (2015-07-21),

Title: Innovations by Vu Van Ma in Cancer Treatment

Introduction

Vu Van Ma, based in Oak Park, CA, is an accomplished inventor with a remarkable portfolio of 22 patents. His work primarily focuses on developing innovative solutions for cancer treatment, showcasing his commitment to advancing medical science through his inventions.

Latest Patents

Among Vu Van Ma's latest patents are several groundbreaking inventions that target specific aspects of cancer biology. One significant patent involves "Substituted piperazines as KRAS G12C inhibitors." This invention provides compositions and methods utilizing KRAS G12C inhibitors, which are useful in treating various disorders, including pancreatic, colorectal, and lung cancers. Another notable patent is for "KIF18A inhibitors," which comprises compounds capable of modulating the KIF18A protein. This modulation impacts the cell cycle and cell proliferation, presenting a promising approach to treat cancer and cancer-related diseases. The patent includes pharmaceutical compositions and methods for addressing disease states tied to KIF18A activity.

Career Highlights

Vu Van Ma's contributions to the field of oncology are significant, as reflected in his impressive number of patents. His work at Amgen Inc. places him at the forefront of pharmaceutical innovation, where he collaborates with a team dedicated to developing effective therapies for complex diseases.

Collaborations

During his tenure at Amgen Inc., Vu Van Ma has had the opportunity to work alongside talented colleagues, including Jian Jeffrey Chen and Ana Elena Minatti. Together, they strive to push the boundaries of conventional cancer treatments, fostering a collaborative environment that encourages innovative thinking and problem-solving.

Conclusion

Vu Van Ma's inventive spirit and dedication to cancer research demonstrate the vital role of innovation in addressing significant health challenges. His patents not only contribute to the scientific community but also pave the way for potential breakthroughs in treating devastating diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…